secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001213900-23-027540
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q1 2023 sales $3.45M, down 43% YoY; backlog rises to $7.5M
-------------------------------------------------------------------

- Q1 2023 sales $3.45M vs $6.00M in Q1 2022, a 43% decrease due to production slowdown from contamination events.
- Trailing twelve months sales $16.01M vs $21.14M, down 24%.
- Backlog of orders increased to $7.5M as of March 31, 2023, from $2.5M at Dec 31, 2022.
- Quality control improvements: first test pass rate 82%, subsequent tests 100% success; production ramping up in Q2.
- Expects third submission of CMC Technical Section for Re-Tain FDA approval around end of April 2023, subject to six-month review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390023027540/0001213900-23-027540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390023027540/ea176604-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-027540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer